Virax Biolabs and Transcode Therapeutics Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV

$RNAZPress releaseAug 7, 2026, 9:00 AM ETRead the release

TransCode Therapeutics CEO Philippe Calais is scheduled to appear on the RedChip Small Stocks, Big Money show to discuss the company's strategic evolution. Calais will highlight the advancement of lead candidate TTX-MC138 into a Phase 2a clinical trial targeting ctDNA positive colorectal cancer patients following curative intent therapy.

Key figures

Drug Name: TTX-MC138
Phase Of Trial: Phase 2a

AI analysis

Red flags2 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.